Your browser is no longer supported. Please, upgrade your browser.
MDGL Madrigal Pharmaceuticals, Inc. daily Stock Chart
Madrigal Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-6.81 Insider Own2.40% Shs Outstand15.43M Perf Week-4.66%
Market Cap1.66B Forward P/E- EPS next Y-12.75 Insider Trans-7.24% Shs Float12.51M Perf Month-3.14%
Income-105.00M PEG- EPS next Q-2.46 Inst Own97.90% Short Float23.51% Perf Quarter40.12%
Sales- P/S- EPS this Y-145.90% Inst Trans-1.85% Short Ratio15.14 Perf Half Y18.83%
Book/sh24.98 P/B4.14 EPS next Y-24.10% ROA-23.60% Target Price176.29 Perf Year3.41%
Cash/sh25.51 P/C4.05 EPS next 5Y0.00% ROE-24.70% 52W Range56.82 - 127.25 Perf YTD13.50%
Dividend- P/FCF- EPS past 5Y29.20% ROI- 52W High-18.73% Beta1.30
Dividend %- Quick Ratio15.90 Sales past 5Y- Gross Margin- 52W Low82.00% ATR5.39
Employees29 Current Ratio15.90 Sales Q/Q- Oper. Margin- RSI (14)43.35 Volatility4.61% 4.85%
OptionableYes Debt/Eq0.00 EPS Q/Q-138.60% Profit Margin- Rel Volume0.58 Prev Close99.78
ShortableYes LT Debt/Eq0.00 EarningsMay 07 BMO Payout- Avg Volume194.19K Price103.41
Recom2.10 SMA20-5.11% SMA50-5.30% SMA20010.67% Volume113,338 Change3.64%
Jun-05-20Initiated BMO Capital Markets Market Perform $135
May-05-20Initiated Chardan Capital Markets Buy $205
Jan-30-20Initiated Canaccord Genuity Buy $198
Jan-09-20Upgrade UBS Neutral → Buy $125 → $127
Nov-07-19Reiterated H.C. Wainwright Buy $225 → $215
Jun-25-19Initiated Stifel Hold
Jun-10-19Upgrade B. Riley FBR Neutral → Buy $128
Feb-28-19Reiterated H.C. Wainwright Buy $313 → $228
Feb-22-19Initiated SVB Leerink Outperform $165
Jan-23-19Initiated UBS Neutral $119
Dec-14-18Initiated Wolfe Research Outperform
Dec-12-18Initiated B. Riley FBR Neutral $124
Nov-19-18Downgrade Raymond James Mkt Perform → Underperform
Nov-16-18Upgrade Evercore ISI In-line → Outperform
Sep-04-18Initiated Citigroup Buy $340
Aug-06-18Downgrade Goldman Buy → Neutral
Jun-28-18Initiated Raymond James Mkt Perform
Jun-19-18Downgrade Evercore ISI Outperform → In-line
Jun-01-18Upgrade Oppenheimer Perform → Outperform
Jun-01-18Reiterated ROTH Capital Buy $210 → $400
Jun-27-20 10:19PM  
Jun-17-20 07:10PM  
Jun-15-20 05:19PM  
Jun-06-20 12:29PM  
May-28-20 08:07AM  
May-14-20 05:31PM  
May-10-20 03:18PM  
May-07-20 06:50AM  
May-05-20 11:00AM  
Apr-14-20 06:50AM  
Mar-30-20 06:06PM  
Feb-28-20 10:49AM  
Feb-26-20 06:50AM  
Feb-05-20 04:11PM  
Jan-21-20 01:27PM  
Dec-19-19 07:28PM  
Dec-18-19 06:50AM  
Dec-13-19 06:20AM  
Dec-10-19 11:58PM  
Nov-29-19 08:41AM  
Nov-11-19 05:30PM  
Nov-06-19 06:50AM  
Oct-26-19 01:22PM  
Sep-19-19 03:28PM  
Aug-07-19 06:50AM  
Jul-11-19 06:50AM  
Jul-10-19 01:26PM  
Jul-02-19 06:50AM  
Jun-19-19 09:07PM  
Jun-07-19 01:29PM  
Jun-04-19 06:50AM  
May-15-19 04:42PM  
May-08-19 10:14AM  
May-01-19 12:49PM  
Apr-08-19 06:50AM  
Apr-06-19 08:03AM  
Mar-28-19 06:50AM  
Mar-01-19 11:49AM  
Feb-27-19 01:25PM  
Feb-20-19 08:11AM  
Feb-17-19 02:03PM  
Feb-12-19 04:20PM  
Jan-11-19 08:59AM  
Jan-08-19 05:13PM  
Dec-28-18 04:52PM  
Dec-12-18 11:03PM  
Dec-08-18 03:03PM  
Nov-28-18 08:40AM  
Nov-23-18 09:15PM  
Nov-19-18 08:15PM  
Nov-14-18 08:31AM  
Nov-12-18 03:37PM  
Nov-06-18 06:50AM  
Oct-27-18 07:18AM  
Oct-19-18 08:15AM  
Sep-26-18 03:21PM  
Sep-20-18 08:48AM  
Sep-19-18 08:00AM  
Sep-18-18 03:00PM  
Sep-12-18 09:17AM  
Aug-19-18 09:02AM  
Aug-07-18 10:22AM  
Aug-06-18 03:05PM  
Jul-30-18 02:39PM  
Jul-26-18 01:33PM  
Jul-17-18 07:35AM  
Jul-14-18 07:16AM  
Jul-11-18 09:15AM  
Jul-03-18 08:10AM  
Jul-02-18 03:23PM  
Jun-26-18 11:27AM  
Jun-23-18 10:21AM  
Jun-18-18 11:45AM  
Jun-15-18 02:31PM  
Jun-14-18 10:30AM  
Jun-13-18 11:23AM  
Jun-06-18 11:14PM  
Jun-05-18 04:10PM  
Jun-04-18 09:44AM  
Jun-03-18 11:35AM  
Jun-02-18 04:10PM  
Jun-01-18 08:16AM  
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAY CITY CAPITAL LLC10% OwnerDec 13Sale105.471,200,000126,564,00088,152Dec 13 02:18 PM
CRAVES FRED BDirectorDec 13Sale105.471,200,000126,564,00088,152Dec 13 02:08 PM